Clinical Trial Update: Safety and Immunogenicity Study of 23-valent Pneumococcal Polysaccharide Vaccine in Healthy Children, Adults and Elderly [Phase 3]

View source ↗

Summary

A Phase 3 trial update reports on the safety and immunogenicity of a 23-valent pneumococcal polysaccharide vaccine in healthy children, adults, and the elderly;…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumococcal Infections

Drugs mentioned

• 23-valent pneumococcal polysaccharide vaccine (Pneumococcal polysaccharide vaccine 23-valent)

Snippet

Sponsor: Sinovac Biotech Co., Ltd | Conditions: Pneumococcal Infections | Phase 3 | Status: COMPLETED